XML 107 R76.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Information and Concentration of Business Risk (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2015
USD ($)
Segment
Partner
Dec. 31, 2014
USD ($)
Partner
Dec. 31, 2013
USD ($)
Segment Information and Concentration of Business Risk [Abstract]                      
Number of reportable segments | Segment                 2    
Revenue [Abstract]                      
Research and development                 $ 281,360 $ 202,514 $ 144,194
Licensing and royalty                 2,343 11,647 3,091
Total revenue $ 51,571 $ 49,121 $ 120,428 $ 62,583 $ 84,861 $ 44,063 $ 57,076 $ 28,161 283,703 214,161 147,285
Loss from operations (62,940) $ (48,138) $ 44,646 $ (9,330) 10,080 $ (21,493) $ (6,650) $ (29,667) (75,762) (47,730) (51,666)
Total assets 956,105       $ 955,809       956,105 955,809  
Operating Segments [Member] | Ionis Core [Member]                      
Revenue [Abstract]                      
Research and development                 285,608 202,514 147,380
Licensing and royalty                 2,343 11,647 3,091
Total revenue                 287,951 214,161 150,471
Loss from operations                 (21,378) (26,033) (38,764)
Total assets 1,004,150               1,004,150    
Operating Segments [Member] | Akcea Therapeutics [Member]                      
Revenue [Abstract]                      
Research and development                 0 0 0
Licensing and royalty                 0 0 0
Total revenue                 0 0 0
Loss from operations                 (54,384) $ (21,697) $ (12,902)
Total assets 55,354               55,354    
Elimination of Intercompany Activity [Member]                      
Revenue [Abstract]                      
Research and development                 (4,248)    
Licensing and royalty                 0    
Total revenue                 (4,248)    
Loss from operations                 0    
Total assets $ (103,399)               $ (103,399)    
Revenue [Member] | Partner A [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 37.00% 58.00% 25.00%
Revenue [Member] | Partner B [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 33.00% 0.00% 0.00%
Revenue [Member] | Partner C [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 12.00% 17.00% 24.00%
Revenue [Member] | Partner D [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 11.00% 4.00% 3.00%
Revenue [Member] | Partner E [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 2.00% 13.00% 20.00%
Revenue [Member] | Partner F [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 0.00% 0.00% 22.00%
Contracts Receivables [Member] | Significant Partners [Member]                      
Significant Partners [Abstract]                      
Concentration percentage                 99.00% 99.00%  
Number of significant partners | Partner                 2 3